Grebb J A, Shelton R C, Freed W J
J Neural Transm. 1987;68(3-4):241-55. doi: 10.1007/BF02098501.
Chronic thioridazine treatment in animals has been reported to produce less dopaminergic supersensitivity than other neuroleptics. This difference may be due to the potent calcium channel inhibitory effect of thioridazine. To test this hypothesis Swiss-Webster mice were treated chronically (28 d) with calcium channel inhibitors (CCI's) - diltiazem, nifedipine or verapamil - with or without haloperidol. Following three days of drug withdrawal, mice were tested for amphetamine-induced locomotion and apomorphine-induced cage climbing. Co-administration of diltiazem or verapamil (but not nifedipine) prevented the development of haloperidol-induced behavioral supersensitivity to apomorphine. Co-administration of CCI's with haloperidol did not affect the development of amphetamine supersensitivity. These data support the hypothesis that co-administration of haloperidol and a CCI (verapamil or diltiazem, but not nifedipine) would mimic the effects of thioridazine treatment alone.
据报道，与其他抗精神病药物相比，动物长期接受硫利达嗪治疗产生的多巴胺能超敏反应较少。这种差异可能是由于硫利达嗪具有强大的钙通道抑制作用。为了验证这一假设，将瑞士韦伯斯特小鼠长期（28天）用钙通道抑制剂（CCI）——地尔硫卓、硝苯地平或维拉帕米——单独或与氟哌啶醇联合治疗。停药三天后，测试小鼠对苯丙胺诱导的运动和阿扑吗啡诱导的笼内攀爬反应。地尔硫卓或维拉帕米（而非硝苯地平）与氟哌啶醇联合给药可预防氟哌啶醇诱导的对阿扑吗啡行为超敏反应的发生。CCI与氟哌啶醇联合给药不影响苯丙胺超敏反应的发生。这些数据支持以下假设：氟哌啶醇与CCI（维拉帕米或地尔硫卓，而非硝苯地平）联合给药将模拟单独使用硫利达嗪治疗的效果。
